The results of these lines of experimentation suggest that for a subset of cancers, inhibition of PI3K/AKT/mTOR signaling can dramatically increase the efficacy of kinesin-5 inhibitors in driving mitotic cell death. The gene discussed is AKT1; the disease is cancer.